Nutt D, Carhart-Harris R. The current status of psychedelics in psychiatry. JAMA Psychiatry. 2021;78:121–2.
Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2023;28:44–58.
Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104–12.
Hunt DL, Castillo PE. Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol. 2012;22:496–508.
Article CAS PubMed PubMed Central Google Scholar
Popik P, Holuj M, Nikiforuk A, Kos T, Trullas R, Skolnick P. 1-Aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats. Psychopharmacol. 2015;232:1025–38.
Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch psychiatry Clin Neurosci. 2013;263:367–77.
Chan SY, Matthews E, Burnet PW. ON or OFF?: modulating the N-methyl-D-aspartate receptor in major depression. Front Mol Neurosci. 2017;9:169.
Article PubMed PubMed Central Google Scholar
De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018;242:69–96.
Aleksandrova LR, Phillips AG. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol Sci. 2021;42:929–42.
Article CAS PubMed Google Scholar
Lambe EK, Aghajanian GK. Hallucinogen-induced UP states in the brain slice of rat prefrontal cortex: role of glutamate spillover and NR2B-NMDA receptors. Neuropsychopharmacology. 2006;31:1682–9.
Article CAS PubMed Google Scholar
Zhang C, Marek GJ. AMPA receptor involvement in 5-hydroxytryptamine2A receptor-mediated pre-frontal cortical excitatory synaptic currents and DOI-induced head shakes. Prog Neuro-Psychopharmacol Biol Psychiatry. 2008;32:62–71.
Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.
Article CAS PubMed PubMed Central Google Scholar
Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology. 2023;226:109422.
Article CAS PubMed Google Scholar
Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032–41.
Article CAS PubMed PubMed Central Google Scholar
Durrant AR, Heresco-Levy U. D-Serine in neuropsychiatric disorders: new advances. Adv. Psychiatry 2014;2014:1–16.
Cheng Y-J, Lin C-H, Lane H-Y. Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology 2022;223:109351.
Miller OH, Moran JT, Hall BJ. Two cellular hypotheses explaining the initiation of ketamine’s antidepressant actions: Direct inhibition and disinhibition. Neuropharmacology. 2016;100:17–26.
Article CAS PubMed Google Scholar
Kang H-K, Hyun C-G. Anti-inflammatory effect of d-(+)-cycloserine through inhibition of NF-κB and MAPK signaling pathways in LPS-induced RAW 264.7 macrophages. Nat Prod Commun. 2020;15:1934578X20920481.
Kurita K, Ohta H, Shirakawa I, Tanaka M, Kitaura Y, Iwasaki Y, et al. Macrophages rely on extracellular serine to suppress aberrant cytokine production. Sci Rep. 2021;11:1–14.
Rolland B, Jardri R, Amad A, Thomas P, Cottencin O, Bordet R. Pharmacology of hallucinations: several mechanisms for one single symptom? BioMed Res Int. 2014;2014:307106.
Article PubMed PubMed Central Google Scholar
Dall’Olio R, Gaggi R, Bonfante V, Gandolfi O. The non-competitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol. 1999;10:63–71.
Dall’Olio R, Gandolfi O, Gaggi R. D-cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behav Pharmacol. 2000;11:631–7.
Nakao K, Singh M, Sapkota K, Fitzgerald A, Hablitz JJ, Nakazawa K. 5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction. Transl Psychiatry. 2022;12:168.
Article CAS PubMed PubMed Central Google Scholar
McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21:463–73.
Article CAS PubMed Google Scholar
Holze F, Ley L, Müller F, Becker AM, Straumann I, Vizeli P, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022;47:1180–7.
Article CAS PubMed PubMed Central Google Scholar
Stroebel D, Paoletti P. Architecture and function of NMDA receptors: an evolutionary perspective. J Physiol. 2021;599:2615–38.
Article CAS PubMed Google Scholar
Geoffroy C, Paoletti P, Mony L. Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential. J Physiol. 2022;600:233–59.
Article CAS PubMed Google Scholar
Dodd S, Norman TR, Eyre H, Stahl SM, Phillips A, Carvalho AF, et al. Psilocybin in Neuropsychiatry: a review of its pharmacology, safety and efficacy. CNS Spectrums 2022;28:1–36.
Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642–51.
Article CAS PubMed Google Scholar
Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535–44.
Article CAS PubMed PubMed Central Google Scholar
Ly C, Greb A, Cameron L, Wong J, Barragan E, Wilson P, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.
Article CAS PubMed PubMed Central Google Scholar
Catlow BJ, Song S, Paredes DA, Kirstein CL, Sanchez-Ramos J. Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res. 2013;228:481–91.
Article CAS PubMed Google Scholar
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402–11.
Article CAS PubMed Google Scholar
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637–48.
Article CAS PubMed Google Scholar
Mann JJ. Is psilocybin an effective antidepressant and what is its Mechanism of action? Cell Rep Med. 2023;4:100906.
Mothet J-P, Parent AT, Wolosker H, Brady RO Jr, Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci. 2000;97:4926–31.
Article CAS PubMed PubMed Central Google Scholar
Wei I-H, Chen K-T, Tsai M-H, Wu C-H, Lane H-Y, Huang C-C. Acute amino acid D-serine administration, similar to ketamine, produces antidepressant-like effects through identical mechanisms. J Agric food Chem. 2017;65:10792–803.
Article CAS PubMed Google Scholar
Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2012;15:1135–48.
Article CAS PubMed Google Scholar
Otte D-M, Barcena de Arellano ML, Bilkei-Gorzo A, Albayram Ö, Imbeault S, Jeung H, et al. Effects of chronic D-serine elevation on animal models of depression and anxiety-related behavior. PloS one. 2013;8:e67131.
Article CAS PubMed PubMed Central Google Scholar
Wolosker H, Balu DT. D-Serine as the gatekeeper of NMDA receptor activity: implications for the pharmacologic management of anxiety disorders. Transl Psychiatry. 2020;10:184.
Comments (0)